转移性去势抵抗性前列腺癌男性患者对镭-223二氯化物的临床反应
该研究回顾性分析了48例接受镭-223治疗的转移性去势抵抗性前列腺癌患者,评估疼痛反应的可能性、时间过程、预测因素及预后价值。结果显示62.5%的患者疼痛较基线减轻,其中96%在第三周期前出现改善;疼痛缓解与碱性磷酸酶或前列腺特异性抗原下降及生存无关。
要点
- 约三分之二接受镭-223治疗的患者疼痛改善,且多在前两个周期内出现。
- 疼痛缓解与碱性磷酸酶或前列腺特异性抗原下降及生存无关联。
- 疼痛反应不应作为评估镭-223疗效的指标。
核心结论
- 约三分之二接受镭-223治疗的患者疼痛改善,若发生则最可能在前两个周期内出现。
- 疼痛反应与生存无关,不应据此评估治疗有效性。
研究设计与样本
- 回顾性病历 Review,纳入本科室接受镭-223治疗的患者48例,计划6周期,每次给药剂量50-55 kBq/kg。
主要发现
- 48例中27例(56%)完成全部6周期计划治疗。
- 自首次治疗起中位生存16.0个月(95%CI 8.9至19.2个月)。
- 33%的患者在治疗期间或之后经历至少一次症状性骨骼事件。
- 62.5%的男性报告疼痛较治疗前基线减轻。
- 疼痛改善的男性中96%在第三周期前出现改善。
临床怎么用
- 作者建议应就疼痛改善的时间线对患者进行咨询。
- 作者建议若疼痛未改善,可考虑姑息性放疗和口服镇痛药调整。
- 作者认为疼痛反应不应作为评估治疗有效性的指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE/OBJECTIVE: Radium-223 prolongs survival and decreases symptomatic skeletal events in men with metastatic castrate-resistant prostate cancer and is indicated in patients with painful bone metastases. However, pain responses are rarely reported and often asked about by patients. Further, patients and their physicians are concerned about a lack of pain response portending a poor treatment response and may be inclined to change systemic therapies before completing 6 cycles. We evaluated the likelihood and time course of pain response, potential predictors of response, and its prognostic value in patients receiving radium-223. MATERIALS AND METHODS: We reviewed the charts of patients who received radium-223 in our department. All patients were planned for 6 cycles with a prescribed dose of 50-55 kBq/kg at each administration. Pain scores, subjective response to pain, analgesic use, treatment toxicities, and laboratory values were recorded at each visit. Symptomatic skeletal events and survival were also recorded. RESULTS: 48 patients received at least one cycle of radium-223 and 27 (56%) received all 6 planned cycles. Median survival from first treatment was 16.0 months (95% CI 8.9 to 19.2 months). 33% experienced at least one symptomatic skeletal event during or after treatment. 62.5% of men reported a decrease in pain from pre-treatment baseline. Of men with improved pain, 96% experienced an improvement before the third cycle. Pain relief was not associated with a decrease in ALK-P or PSA or improved survival. CONCLUSIONS: Approximately two-thirds of patients who undergo treatment with radium-223 will experience an improvement in pain and, if it occurs, it will most likely occur within the first two cycles. Patients should be counseled about this timeline and, if pain improvement isn't achieved, palliative radiation and oral analgesic readjustment should be considered. Pain response is not associated with survival and should not be used to evaluate the effectiveness of treatment.
引用
- Zhang I, Gilbo P, Kohn N, et al. Clinical response to radium-223 dichloride in men with metastatic castrate-resistant prostate cancer. Pract Radiat Oncol. 2018. PMID: 29934137. doi:10.1016/j.prro.2018.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。